Posters

October 11, 2023

VT3989, a clinical TEAD palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and PI3K/AKT/mTOR pathways

Research and Publications

Publications and Presentations

March 7, 2013

The Hippo Pathway and Human Cancer

Publications and Presentations

November 5, 2015

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

News

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics